Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues for the first quarter of 2024, reaching $1.6 billion, excluding the impact of foreign exchange. This growth was primarily fueled by a robust performance in Women’s Health and Biosimilars segments, which saw revenues surge 12% and 46% to $422 million and $170 million, respectively. Meanwhile, Established brands experienced a more modest 2% increase, reaching $1.0 billion over the quarter, slightly hindered by a $5 million impact from China’s Volume-Based Procurement (VBP) scheme.
The company’s top-performing products in Q1 included the contraceptive Nexplanon (etonogestrel implant), which generated $220 million in global sales, the antihypertensive Atozet (ezetimibe + atorvastatin) with $132 million, and the asthma treatment Singulair (montelukast) at $98 million.
Geographically, Europe and Canada led the way with a 10% YOY increase to $450 million, followed by the United States with a 14% rise to $371 million. The Asia Pacific and Japan region reported a 7% decline to $287 million, while Latin America, Middle East, Russia, and Africa saw a significant 36% growth, contributing $274 million. China’s revenues dipped by 5% to $206 million; however, the company anticipates full-year growth, bolstered by a double-digit increase in the fertility franchise during Q1, particularly in provinces like Beijing where assisted reproductive technologies are covered by reimbursements.- Flcube.com
